FDA Approves Opdivo for Hard-to-Treat Hodgkin Lymphoma

By Hope Cristol Patients with hard-to-treat Hodgkin lymphoma now have a new treatment option. The U.S. Food and Drug Administration granted accelerated approval to Opdivo (nivolumab) for classic Hodgkin lymphoma that has returned or progressed after a specific type of stem cell transplant and post-transplant medicine. Hodgkin lymphoma is a cancer of the lymph system, which is part of the immune system. There are two main types of this disease, but “classic” Hodgkin lymphoma accounts for about 95% of all cases in developed countries. The American Cancer Society estimates about 8,500 new cases of Hodgkin lymphoma will be diagnosed in 2016, with a 5-year survival rate ranging from 90% for stage I to 65% for stage IV. When Hodgkin lymphoma comes back after treatment (relapsed disease) or doesn’t go away after treatment (refractory disease), the next step is often an autologous stem cell transplant. This treatment uses high doses of chemotherapy, followed by reinfusing a patients’ own blood and marrow stem cells back into the body. The anticancer drug Adcetris (brentuximab vedotin) may be given to patients post-transplant. Opdivo, an immunotherapy drug, can now be used for Hodgkin lymphoma if these treatments don’t work. In clinical trials that formed the basis of the new approval, 95 patients with relapsed or refractory disease were treated with Opdivo. It was found to shrink tumors in 65% of patients: 58% achieved partial remission and 7% achie...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Hodgkin Disease Source Type: news

Related Links:

Immunotherapy has already revolutionized cancer care. Combining various immunotherapies promises even greater success, but will the already high cost of these therapies put combos out of reach?Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
PROSTATE cancer symptoms don ’t always appear in the early stages until the tumour has grown and put pressure on other parts of the body. When this happens, pain in certain parts of the body may begin to show.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Parashar P, Tripathi CB, Arya M, Kanoujia J, Singh M, Yadav A, Kumar A, Guleria A, Saraf SA Abstract Co-therapy through biotin modified nanoparticles (NPs) of gefitinib (Gnb) and naringenin (Nar) was investigated for its therapeutic and synergistic potential against lung cancer. The biotin-conjugated polymeric NPs (bty-Nar/Gnb) were developed using oil in water emulsion technique and optimized using central composite design. The formulations were subjected to various in vitro (A549 cell lines) and in vivo evaluations in urethane-induced lung cancer. Co-administration of Gnb and Nar NPs displayed a signific...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
PROSTATE cancer symptoms don ’t always appear in the early stages until the tumour has grown and put pressure on other parts of the body. When this happens, pain in certain parts of the body may begin to show.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
After a double mastectomy, Catherine Guthrie wanted to retain her strength and challenge the idea of feminine norms.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Breast Cancer Women and Girls Mastectomy Surgery and Surgeons Muscles Source Type: news
ConclusionCRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Declan Dunne, Claire Knowles
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Liz Baker, Norma Robinson, Mohamed Tabaqchali, David Leaper
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Liz Baker, Louise Hall, Deborah Wilson, Pud Bhaskar
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Baek Kim
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Food and Drug Administration (FDA) | Hodgkin's Disease | Immunotherapy | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Lung Cancer | Lung Transplant | Lymphoma | Melanoma | Non-Small Cell Lung Cancer | Respiratory Medicine | Skin Cancer | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Urology & Nephrology